OSAKA, Japan, July 30, 2015 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone
containing medicines, including ACTOS (pioglitazone
HCI) with up to 10 years of follow-up.
Rosiglitazone use was curbed due to heart concerns, although restrictions were later lifted, while pioglitazone
was hit by concerns over a possible link to bladder cancer.
In the phase III, randomized, placebo-controlled, double-blind PIVENS trial, vitamin E therapy was compared to pioglitazone
and placebo in 247 nondiabetic adults (N.
is indicated as second or third line treatment of type 2 diabetes as monotherapy and dual oral therapy.
hydrochloride was obtained as a gift sample (Cipla Pharmaceuticals Ltd, India).
8 percent, similar to those on linagliptin plus pioglitazone
During the study, scientists conducted some tests on type 2 diabetes patients, who consumed pioglitazone
and they were compared with patients who consumed rosiglitazone, another type 2 diabetes drug.
But like several other hypoglycemic agents; pioglitazone
therapy also causes weight gain.
Based on their knowledge that NASH arises from persistent insulin resistance and oxidative stress, they examined the effects of pioglitazone
(Actos[R]), an insulin-sensitizing drug, and vitamin E.
Our study shows that increased fracture risk is associated with higher TZD dose, but no difference between rosiglitazone and pioglitazone
is apparent, suggesting a class effect of TZDs on fracture risk," senior author William Herman, also of the university, said in a prepared statement.
was not superior to placebo, but it did lower alanine levels.
The drugs rosilglitazone and pioglitazone
are being compared at 10 sites in India -- Bangalore, Karnal, Kottayam, Vijaywada, Mumbai, Nasik, Pune, Trichy, and two sites in Kochi -- to see if rosiglitazone is associated with more risk for patients.